Physician profile
David T Ade
NPI 1972589042
$5,908.76
in general payments reported to CMS, 2019-2025
53 companies · $39.19 in 2025
The $39.19 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $716 · 2021: $1,812 · 2022: $1,452 · 2023: $1,276 · 2024: $213 · 2025: $39.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $887.90 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Amgen INC. | $562.06 | 2019-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.52 | 2019-2023 | Jardiance, Ofev |
| Abbvie INC. | $378.93 | 2021-2024 | Ubrelvy, Vraylar |
| Astellas Pharma US INC | $310.30 | 2020-2023 | Veozah |
| Ironwood Pharmaceuticals, INC | $254.38 | 2021-2023 | Linzess |
| Glaxosmithkline, LLC. | $251.34 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $230.05 | 2019-2023 | |
| Allergan, INC. | $220.03 | 2019-2020 | |
| Novo Nordisk INC | $181.91 | 2020-2023 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $168.33 | 2021-2023 | |
| Amarin Pharma, INC. | $146.96 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $142.21 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $135.89 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.46 | 2021-2023 | Xifaxan, Trulance |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.